Jackson Egen discovered the significance of fundamental lab research during his graduate studies at UC Berkeley in the 1990s, working under the guidance of esteemed immunologist James Allison. “Jim emphasized that more effective cancer immunotherapies could arise from a deep…
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced that it will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024, taking place from September 13-17, 2024, in Barcelona, Spain. The presentations will highlight advancements in solid tumor…
Stolen contact lenses sold through fake online pharmacies, prescription medications missing active ingredients, and surgical sutures made from substandard materials are just a few examples of counterfeit healthcare products that plague the global market. This illicit industry generates an estimated…
OMNY Health, a leader in creating compliant cross-industry data partnerships, has announced the launch of its Glucagon-Like Peptide-1 (GLP-1) data network, reinforcing its mission to democratize healthcare data. This new network, encompassing over 600,000 patients, will empower OMNY’s partners in…
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced the top-line results from a Phase 3 open-label, single-arm trial conducted in Japan. The study assessed the safety and efficacy of their cannabidiol oral solution, marketed globally as Epidiolex®/Epidyolex®, as an adjunctive treatment…
AstraZeneca’s IMFINZI® (durvalumab) Approved in the US for Comprehensive Treatment of Resectable Non-Small Cell Lung Cancer AstraZeneca has announced that IMFINZI® (durvalumab), in combination with chemotherapy, has received approval from the US Food and Drug Administration (FDA) for the treatment…
Agendia is pleased to announce that it has achieved certification from the European Union (EU) In Vitro Diagnostic Medical Device Regulation (IVDR) for three of its products: the MammaPrint® FFPE Microarray, BluePrint® FFPE Microarray, and the MammaPrint® and BluePrint® NGS…
BioNTech SE (Nasdaq: BNTX) today revealed top-line results from their Phase 3 clinical trial evaluating a combined mRNA vaccine candidate against influenza and COVID-19 in healthy adults aged 18-64. This combination vaccine includes Pfizer’s mRNA-based influenza candidate and the companies’…
WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Medigene AG (FSE: MDG1, Prime Standard) have announced a three-year strategic partnership. The collaboration aims to design and co-research T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs)…
ILiAD Biotechnologies, a biotech company developing the most advanced next-generation pertussis vaccine (BPZE1), announced today that Fierce Biotech has named the company to its Fierce 15 2024 list, recognizing ILiAD as one of the most promising and innovative biotechnology companies…
BioNTech Announces Promising Phase 2 Results for mRNA Immunotherapy BNT111 in Advanced Melanoma BioNTech today revealed positive topline data from its ongoing Phase 2 clinical trial (EudraCT No.: 2020-002195-12; NCT04526899) involving patients with unresectable stage III or IV melanoma whose…
Today, Eisai Co. Ltd. presented new findings on lecanemab-irmb (branded as LEQEMBI® in the U.S.) at the Alzheimer’s Association International Conference (AAIC) 2024 in Philadelphia and online. This dual-acting anti-amyloid beta (Aβ) protofibril antibody is designed for early Alzheimer’s disease…